By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Global Blood Therapeutics 

455 Mission Bay Blvd South
Suite 575
San Francisco  California  94158  U.S.A.
Phone: 415-766-3600 Fax: n/a


Global Blood Therapeutics is developing novel, orally-available therapeutics designed to change the treatment paradigm for chronic blood diseases. The Company is addressing severe, non-malignant blood-based diseases for which there are currently no effective cures and only extremely limited therapeutic options.

The current standard of care treats the symptoms during acute episodes; however, the underlying pathology of the disease causes progressive damage to the body. Global Blood Therapeutics is focused on the critical need for therapeutics that address the causes of blood diseases, not just the symptoms.

Global Blood Therapeutics’ extensive drug discovery capabilities — combining world-class medicinal chemistry with deep expertise in blood biology — are driving its product pipeline of mechanism-based therapeutics.

The Company has built a pipeline of preclinical programs focused on several blood diseases. Its lead program is in sickle cell disease, a global health challenge with very limited treatment options and none that address the underlying cause of the disease. The Company’s pipeline also includes a novel therapeutic for hereditary angioedema.

Global Blood Therapeutics is a private Company led by an experienced management team with a track record of four successful drug approvals and more than 30 investigational new drug applications. Backed by Third Rock Ventures, the Company was founded in 2012 with a $40.7 million Series A financing.

Key Statistics

Ownership: Private

Web Site: Global Blood Therapeutics
Employees: n/a


Company News
Global Blood Therapeutics Strengthens Management Team With Addition Of Vice President Of Program Leadership And Business Strategy 2/11/2015 3:26:43 PM
Global Blood Therapeutics To Present At 17th Annual BIO CEO & Investor Conference 2/5/2015 12:32:25 PM
Global Blood Therapeutics Announces First Cohort Dosed In Phase 1/2 Trial Of GBT440 In Sickle Cell Disease 1/13/2015 12:40:51 PM
Global Blood Therapeutics To Present At Upcoming Investor Conferences 1/5/2015 9:00:49 AM
Global Blood Therapeutics' GBT440 Demonstrates Ability To Positively Impact Fundamental Sickle Cell Disease (SCD) Processes In Studies Presented At 2014 American Society of Hematology Conference 12/8/2014 11:40:59 AM
Global Blood Therapeutics To Present New Data Highlighting Therapeutic Potential Of GBT440 In Sickle Cell Disease (SCD) At 2014 American Society of Hematology Conference 12/3/2014 2:29:27 PM
Top 30 Life Science Startups To Watch In The U.S. 10/23/2014 4:27:21 AM
Global Blood Therapeutics Names Hing Sham Senior Vice President Of Chemistry, Promotes Uma Sinha To Chief Scientific Officer 8/4/2014 10:04:53 AM
Global Blood Therapeutics Names Ted W. Love As CEO 6/17/2014 10:00:03 AM
Global Blood Therapeutics to Present First Data on its Lead Sickle Cell Disease Program at 55th American Society of Hematology Annual Meeting 11/7/2013 8:42:00 AM